On January 7, Gelonghui reported that DaJia VICOM Ltd (301126.SZ) announced that its holding subsidiary, Hunan Tianji Caotang Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for Oseltamivir phosphate granules approved and issued by the National Medical Products Administration.
The indications for Oseltamivir phosphate are: 1. For the treatment of type A and B influenza in patients aged 2 weeks and older (Oseltamivir phosphate can effectively treat type A and B influenza, but there is limited clinical application data for type B influenza). Patients should use it within 48 hours of the onset of symptoms. 2. For the prevention of type A and B influenza in individuals aged 1 year and older.
Oseltamivir phosphate is classified as a Type B variety in the "National Catalogue of Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drugs (2024 Edition)" and the product has entered the 2018 version of the essential drug list in China.
